Riata Life Sciences Private Limited

Riata Life Sciences Private Limited - pharma in Mumbai, Maharashtra, India. Directors, charges & compliance details.
CIN U15100MH2013PTC402612 Incorporated 03 January 2013 ROC Mumbai HQ Mumbai, Maharashtra, India
Merged Private Limited Company pharma
Data last updated
Revenue · FY 2023
₹16.11 Cr
▲ 21% YoY
Net loss · FY 2023
₹4.78 Cr
Net margin -29.7%
EBITDA · FY 2023
₹4.08 Cr
EBITDA margin 25.3%
Authorised capital
₹37.75 Cr
Registered with MCA
Paid-up capital
₹36.85 Cr
Issued & subscribed
Open charges
₹50 Lakh
Satisfied ₹11 Cr
Company age
13 yrs
Est. 2013
Employees · EPFO
24
Provident fund records

About Riata Life Sciences Private Limited

Data last updated:

Riata Life Sciences Private Limited was a private limited company based in Mumbai, Maharashtra, India, operated as a subsidiary of Synergia Life Sciences Private Limited. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 January 2013.

The company was registered with the Registrar of Companies (ROC), Mumbai, under CIN U15100MH2013PTC402612. Its GSTIN is 24AAGCR2236J1ZG (Gujarat).

The company had an authorised share capital of ₹37.75 Cr and a paid-up capital of ₹36.85 Cr. It was formerly known as Riata Organics Private Limited. It was led by directors including Manish Kumar Mittal and Krishnamohan Puvvada.

Its last annual general meeting (AGM) was held on 12 December 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office was at Mumbai, Maharashtra.

As per the financials filed for FY 2023, the company reported a revenue of ₹16.11 Cr, a growth of 21% compared to the previous year. For the same year it recorded a net loss of ₹4.78 Cr (net margin -29.7%) and EBITDA of ₹4.08 Cr (EBITDA margin 25.3%).

The company had about 24 employees on its provident fund (EPFO) records before it was dissolved.

As per MCA filings, the company had open charges of ₹50 Lakh and satisfied charges of ₹11 Cr on record. The company has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹1.65 Cr; the latest was in March 2016. The company has 7 MSME Form 1 returns on record between 2021 and 2023, listing 218 overdue payments to 50 micro and small suppliers.

The last known website on record is novozymes.com.

Company Details of Riata Life Sciences Private Limited
CIN U15100MH2013PTC402612
Registration Number 402612
Incorporation Date 03 January 2013
ROC Mumbai
Listing Status Unlisted
Company Status Amalgamated
Date of Last AGM 12 December 2024
Date of Balance Sheet 31 March 2024
Parent Company Synergia Life Sciences Private Limited
Compliance Status Active Compliant
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Social Media
    Locked
  • Registered Address
    Unit No 1503 15th Floor Universal Majestic, Pl Lokhande Marg Ghatkopar Mankhurd Link Road Govandi, Mumbai, Maharashtra, India – 400043
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Riata Life Sciences Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Riata Life Sciences Private Limited report

Financials, compliance, directors, charges, ownership and filings for Riata Life Sciences Private Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Financials of Riata Life Sciences Private Limited FY 2024 filings available

Riata Life Sciences Private Limited reported revenue of ₹16.11 Cr (up 21% YoY) for FY 2023.

Revenue · FY 2023
₹16.11 Cr ▲ 21%
Net loss · FY 2023
₹4.78 Cr margin -29.7%
EBITDA · FY 2023
₹4.08 Cr margin 25.3%

Compounded Annual Growth Rate (CAGR) of Riata Life Sciences Private Limited

Revenue CAGR growth
1 year
▲ 21%
EBITDA CAGR growth
1 year
▲ 408%

Revenue rose 21% in the latest year. EBITDA rose 408% in the latest year. All are worked out from the filed statements.

Financial Statement Summary of Riata Life Sciences Private Limited

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profit and Loss Statement
Revenue from Operations₹16.11 Cr••••••••••••••••
Other Income••••••••••••••••••••
Total Revenue••••••••••••••••••••
Cost of Materials Consumed••••••••••••••••••••
Employee Benefit Expense••••••••••••••••••••
Finance Costs••••••••••••••••••••
Depreciation and Amortisation••••••••••••••••••••
Other Expenses••••••••••••••••••••
Total Expenses••••••••••••••••••••
EBITDA₹4.08 Cr••••••••••••••••
Profit Before Tax••••••••••••••••••••
Tax Expense••••••••••••••••••••
Net Profit (PAT)-₹4.78 Cr••••••••••••••••
Balance Sheet
Share Capital••••••••••••••••••••
Reserves and Surplus••••••••••••••••••••
Net Worth (Total Equity)••••••••••••••••••••
Long-term Borrowings••••••••••••••••••••
Short-term Borrowings••••••••••••••••••••
Trade Payables••••••••••••••••••••
Total Liabilities••••••••••••••••••••
Fixed Assets••••••••••••••••••••
Investments••••••••••••••••••••
Inventories••••••••••••••••••••
Trade Receivables••••••••••••••••••••
Cash and Bank Balance••••••••••••••••••••
Total Assets••••••••••••••••••••

Financial Ratios of Riata Life Sciences Private Limited

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profitability
EBITDA Margin25.3%••••••••••••••••
Net Profit Margin-29.7%••••••••••••••••
Return on Equity (ROE)••••••••••••••••••••
Return on Capital Employed (ROCE)••••••••••••••••••••
Return on Assets (ROA)••••••••••••••••••••
Liquidity and Debt
Current Ratio••••••••••••••••••••
Quick Ratio••••••••••••••••••••
Debt-to-Equity Ratio••••••••••••••••••••
Interest Coverage Ratio••••••••••••••••••••
Efficiency and Growth
Asset Turnover••••••••••••••••••••
Receivable Days••••••••••••••••••••
Payable Days••••••••••••••••••••
Inventory Days••••••••••••••••••••
Revenue Growth••••••••••••••••••••
Net Profit Growth••••••••••••••••••••

Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Riata Life Sciences are in the company report.

Premium access

Financial statements from 2015

Earlier years and trend charts are in the company report.

  • Income statements
  • Balance sheets
  • Cash-flow statements
  • Ratios and benchmarks

Verified entity values are shown only after access is granted.

Auditor Details of Riata Life Sciences Private Limited

Riata Life Sciences Private Limited is audited by B S R & Co. LLP for the financial year 2023.

NameStatusAppointment DateCessation Date
B S R & Co. LLPLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Riata Life Sciences Private Limited

Riata Life Sciences has 3 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.

Directors (as last reported)
NameDesignationAppointment DateTenureStatus
Manish Kumar MittalDirector09 Dec 20214 Years 10 MonthsAs last reported
Krishnamohan PuvvadaDirector09 Dec 20214 Years 10 MonthsAs last reported
Sanjay Ajabrao SoorDirector09 Dec 20214 Years 10 MonthsAs last reported

Ownership and Shareholding of Riata Life Sciences Private Limited

Premium access

Shareholding and ownership data

Promoter, institutional, public and beneficial ownership figures are in the company report.

  • Ownership categories
  • Historical changes
  • Group structure
  • FII and DII holdings

Verified entity values are shown only after access is granted.

Charges & Borrowings of Riata Life Sciences Private Limited

Open charges
₹50 Lakh
Satisfied charges
₹11 Cr
Breakdown by lending institutions
Bank of Baroda₹11.00 Cr
Latest charge details
DateLenderAmountStatus
20 Jun 2013Bank of Baroda₹5.5 CrSatisfied
10 Apr 2013Bank of Baroda₹5.5 CrSatisfied

Total charge records: 2 View all charges

Deals & Funding of Riata Life Sciences Private Limited

Riata Life Sciences Private Limited has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹1.65 Cr; the latest was in March 2016.

Total deals
3
Secondary share transfers
2
Funding round
1
Disclosed funding
₹1.65 Cr

Deals on record (2 of 3)

WhenDealAmountParties
Mar 2016Secondary share transferUndisclosedBuyer: Synergia Life Sciences Private Limited, an individual
Seller: Viridis Biopharma Private Limited , 2 individuals
Dec 2013Secondary share transferUndisclosedBuyer: Viridis Biopharma Private Limited
Seller: an individual
Premium access

Full deal history

All 3 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Riata Life Sciences Private Limited

Riata Life Sciences Private Limited has 7 MSME Form 1 returns on record between 2021 and 2023, listing 218 overdue payments to 50 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 50)

SupplierAmount dueDue sinceReported on
an individual supplier••••••••••••
an individual supplier••••••••••••
an individual supplier••••••••••••
an individual supplier••••••••••••
an individual supplier••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 7 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Riata Life Sciences Private Limited

Riata Life Sciences Private Limited has a workforce of 24 employees as of Apr 02, 2024.

Employee count
24
Active EPFO establishments
1
Employee growth
20%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

CIN History of Riata Life Sciences Private Limited

Riata Life Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U15100MH2013PTC402612, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U15100MH2013PTC402612Current
U24100GJ2013PTC073250Previous
U15100GJ2013PTC073250Previous

Recent Activity on Riata Life Sciences Private Limited

Riata Life Sciences Private Limited has 9 board changes on record since 2013: 3 appointments and 6 cessations. The latest: Biren Patel ceased to be Director on 03 Jan 2023.

AGM
Riata Life Sciences Private Limited last Annual general meeting of members was held on 12 Dec 2024 as per latest MCA records.
Filing
Riata Life Sciences Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Ceased
Biren Patel ceased to be Director.
Ceased
Dilip Sukhlal Mehta ceased to be Director.
Appointed
Krishnamohan Puvvada was appointed as Director.
Appointed
Manish Kumar Mittal was appointed as Director.
Appointed
Sanjay Ajabrao Soor was appointed as Director.
Charges
A charge registered on 20 Jun 2013 via Charge ID 10482968 with Bank Of Baroda was fully satisfied on 15 Jan 2018.
Charges
A charge registered on 10 Apr 2013 via Charge ID 10423681 with Bank Of Baroda was fully satisfied on 15 Jan 2018.
Ceased
Anirudh Dilip Mehta ceased to be Additional Director.
Ceased
Anselm Julius Desouza ceased to be Additional Director.
Ceased
Ashit Harshad Vora ceased to be Additional Director.

4 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Riata Life Sciences Private Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Riata Life Sciences Private Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Riata Life Sciences Private Limited

Riata Life Sciences has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
24AAGCR2236J1ZGGujaratActive01 Jul 2017
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Riata Life Sciences Private Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Riata Life Sciences Private Limited

Riata Life Sciences has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.

Riata Life Sciences was a private limited company based in Mumbai, Maharashtra, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 03 January 2013 and is registered under CIN U15100MH2013PTC402612. The company is recorded as amalgamated in MCA records and no longer exists as a legal entity.

Riata Life Sciences was incorporated on 03 January 2013. It is registered with the Registrar of Companies, Mumbai.

Riata Life Sciences had 3 directors:

The CIN (Corporate Identification Number) of Riata Life Sciences is U15100MH2013PTC402612. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

The registered office of Riata Life Sciences is at Unit No 1503 15th Floor Universal Majestic, Pl Lokhande Marg Ghatkopar Mankhurd Link Road Govandi, Mumbai, Maharashtra, India – 400043.

Riata Life Sciences can be reached through the website novozymes.com. Its registered office is in Mumbai, Maharashtra, India.

Riata Life Sciences reported revenue of ₹16.11 Cr for FY 2023 (up 21% YoY).

Riata Life Sciences has an authorised share capital of ₹37.75 Cr and a paid-up capital of ₹36.85 Cr.

Riata Life Sciences reported a net loss of ₹4.78 Cr (net margin -29.7%) and EBITDA of ₹4.08 Cr (EBITDA margin 25.3%) for FY 2023, as per its filed financial statements.

The GSTIN of Riata Life Sciences is 24AAGCR2236J1ZG, registered in Gujarat.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available